Posted by Michael Wonder on 21 Apr 2021
Medtronic receives U.S. FDA approval for pipeline flex embolisation device with shield technology
21 April 2021 - First patient receives new shield surface modification, an advance in flow diversion therapy, at NYU Langone Health.
Medtronic today announced it has received approval from the United States FDA for Pipeline Flex Embolization Device with Shield Technology.
Medtronic developed Shield Technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy by introducing the first surface-modified implant device which demonstrates reduction in material thrombogenicity, a reduction in the tendency of the surface treatment material to create clots.
